No connection

Search Results

HCTI vs ISPC

HCTI
Healthcare Triangle, Inc.
BEARISH
Price
$2.40
Market Cap
$2.8M
Sector
Healthcare
AI Confidence
95%
ISPC
iSpecimen Inc.
BEARISH
Price
$0.13
Market Cap
$3.8M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
HCTI
--
ISPC
--
Forward P/E
HCTI
-0.08
ISPC
-0.16
P/B Ratio
HCTI
0.14
ISPC
0.41
P/S Ratio
HCTI
0.21
ISPC
1.97
EV/EBITDA
HCTI
-1.29
ISPC
0.32

Profitability

Gross Margin
HCTI
13.12%
ISPC
1.25%
Operating Margin
HCTI
-74.26%
ISPC
-5192.87%
Profit Margin
HCTI
-48.84%
ISPC
0.0%
ROE
HCTI
-183.0%
ISPC
-327.77%
ROA
HCTI
-39.27%
ISPC
-59.44%

Growth

Revenue Growth
HCTI
44.6%
ISPC
-96.5%
Earnings Growth
HCTI
--
ISPC
--

Financial Health

Debt/Equity
HCTI
0.18
ISPC
0.09
Current Ratio
HCTI
2.03
ISPC
1.12
Quick Ratio
HCTI
1.94
ISPC
1.11

Dividends

Dividend Yield
HCTI
--
ISPC
--
Payout Ratio
HCTI
0.0%
ISPC
0.0%

AI Verdict

HCTI BEARISH

HCTI presents a classic value trap scenario, characterized by a stable Piotroski F-Score of 4/9 but catastrophic price action and fundamental decay. While the company shows strong top-line revenue growth of 44.6%, it is coupled with a disastrous ROE of -183% and an operating margin of -74.26%. The extreme discrepancy between the 52-week high ($7470) and current price ($2.40) indicates a total collapse in investor confidence or a massive corporate restructuring. Despite low debt and a healthy current ratio, the lack of profitability and negative earnings surprises make this a high-risk speculative asset.

Strengths
Strong YoY revenue growth of 44.60%
Low Debt/Equity ratio of 0.18
Healthy liquidity with a Current Ratio of 2.03
Risks
Catastrophic price performance (-99.9% 1Y change)
Severe negative profitability (Profit Margin -48.84%)
Extreme equity erosion (ROE -183%)
ISPC BEARISH

The company is in severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a total absence of a viable Altman Z-Score. Revenue has collapsed by 96.50% year-over-year, while operating margins have plummeted to -5192.87%, indicating a complete breakdown of the business model. With a 5-year price decline of 99.9% and a technical trend score of 0/100, the stock is in a terminal bearish phase. Despite a low debt-to-equity ratio, the lack of top-line growth and extreme losses make the equity highly speculative and high-risk.

Strengths
Low Debt/Equity ratio (0.09) suggests minimal long-term debt burden
Current Ratio of 1.12 indicates marginal short-term liquidity
Trading at a discount to book value (P/B 0.41)
Risks
Catastrophic revenue decline of -96.50% YoY
Extreme operational inefficiency with -5192.87% operating margin
Severe financial instability indicated by Piotroski F-Score of 1/9

Compare Another Pair

HCTI vs ISPC: Head-to-Head Comparison

This page compares Healthcare Triangle, Inc. (HCTI) and iSpecimen Inc. (ISPC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile